Skip to main content Help with accessibility Skip to main navigation

Denosumab 120mg

Indication

Prevention of skeletal-related events in adults with bone metastases from solid tumours (NICE TA265)

NICE TA265 - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours 

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab (Xgeva▼) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate

MHRA Drug Denosumab (Xgeva▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation

Amber level 1

Brand:

Xgeva®

Nice TA:

265

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

Recommendation

LSCMMG Recommendation:

Amber level 1

Reason for decision:

Shared care required

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Amber 1
Amber 1
Amber 1
Amber 1
Amber 1
Amber 1
Amber 1
Amber 1
What do the colours mean?

Last Updated: 13 - Feb - 2024